This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BT-063

Biotest AG

Drug Names(s): BT-063

Description: BT-063 is being developed for the lead indication of systemic lupus erythematosus (SLE). The monoclonal antibody specifically neutralises a cell growth factor which plays an important role in the development and symptoms of the disease.


BT-063 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug